VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples, supporting early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company noted that the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. According to Volition, this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs. Early detection is critical for improving patient outcomes, yet many regions lack the laboratory infrastructure needed for timely diagnosis. Volition's finger-prick prototype could enable testing in remote or resource-limited settings, potentially saving lives by allowing earlier intervention.
The company's Nu.Q technology targets nucleosomes, which are structural units of DNA that are released into the bloodstream during cell death. Elevated levels of nucleosomes have been associated with sepsis and other conditions involving NETosis, a form of cell death that contributes to inflammation. Volition is developing simple, cost-effective blood tests to detect and monitor a range of diseases, including certain cancers and sepsis.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. The company is dedicated to advancing the science of epigenetics and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring.
The full press release is available at https://ibn.fm/ioEmu. For more information about Volition, visit the company's website at www.Volition.com.
